Email Investor Relations| Title | Type | Size | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Compensation Committee Charter |
|
37.2 KB | |||||||
| 2011 Form 10-K |
|
513.9 KB | |||||||
| 2010 Form 10-K |
|
570.9 KB | |||||||
| 2009 Form 10-K/A; Amendment No. 2 |
|
553.7 KB | |||||||
| 2009 Form 10-K/A; Amendment No. 1 |
|
282.8 KB | |||||||
| 2009 Form 10-K |
|
1.5 MB | |||||||
|
|||||||||
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.
© 2018 Celldex Therapeutics, All rights reserved | Site Map | Privacy Policy | Terms of Use | Contact
